Prostate Cancer Clinical Trial
Official title:
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
Background:
- Flutamide is an approved drug for prostate cancer that blocks the effects of
testosterone on prostate cancer cells and may slow the progression of the disease.
- The vaccine in this study consists of a priming vaccine called PROSTVAC (rilimogene
galvacirepvec/rilimogene glafolivec) -V/TRICOM (triad of costimulatory molecules), made
from vaccinia virus, and a boosting vaccine called PROSTVAC-F/TRICOM, made from fowlpox
virus. DNA (Deoxyribonuceic acid) is inserted into the priming and boosting vaccine
viruses to cause production of proteins that enhance immune activity and also to produce
prostate specific antigen (PSA) a protein that is normally produced by the patients
tumor cells.
- GM-CSF (granulocyte macrophage colony stimulating factor), given along with the vaccine,
is a chemical that boosts the immune system. It is used in this study to try to increase
the usefulness of the vaccine by increasing the number of immune cells at the
vaccination site.
Objectives:
-To determine if treatment with a prostate cancer vaccine plus flutamide is more effective
than flutamide alone in delaying disease progression in patients with prostate cancer.
Eligibility:
- Patients 18 years of age and older with androgen-insensitive prostate cancer that has
not spread beyond the prostate gland.
- Patients with a rising PSA (prostatic specific antigen) who have already been treated
with anti-iandrogen therapy (either bicalutamide or nilutamide).
Design:
- There are two treatment groups in this study. Group A receives only flutamide; group B
receive flutamide plus vaccine.
- Patients in both groups receive flutamide by mouth three times a day.
- Patients in group B receive PROSTVAC-V/TRICOM on day 1 and PROSTVAC-F/TRICOM on day 29
and again every 4 weeks. All vaccines are given as injections under the skin.
- Patients have blood tests for PSA levels every month and scans every 3 months until the
disease worsens.
- After 3 months of therapy, patients receiving in group A (flutamide alone) may cross
over to receive vaccine if they develop a rising PSA and scans show no sign of disease
spread. Patients in group B (flutamide plus vaccine) stop flutamide and may continue
vaccine therapy. At this point patients may continue to receive treatment until the
disease progresses or PSA levels rise....
Background:
- There is no standard of care for prostate cancer patients progressing on hormone therapy
with a rising serum PSA (prostatic specific antigen) level without evidence of
metastatic disease.
- We have completed a phase II trial in which men with this stage of disease were
randomized to receive a pox vector PSA vaccine vs. the antiandrogen nilutamide.
- The median time to treatment failure on nilutamide was 7.6 months.
- 12 patients on the vaccine arm had nilutamide added at the time of PSA progression.
- The median time for treatment failure after the addition of nilutamide was 13.9 months,
for a total of 25.9 months from initiation of vaccine therapy.
- This suggests that the combination of hormone therapy with vaccine therapy may lead to
an improved clinical benefit compared to hormone therapy alone.
- Due to the increased toxicity of nilutamide compared to other antiandrogens and the
patients prior exposure to bicalutamide therapy, we plan to use flutamide as a second
line hormonal manipulation in the below study.
Objectives (Primary):
-To determine if use of a combination of vaccine plus flutamide may be associated with a
trend toward improvement in time to treatment failure compared to flutamide alone.
Eligibility:
- Must have non metastatic androgen insensitive prostate cancer with a rising PSA with
castrate levels of testosterone and no evidence of metastatic disease on CT (computed
tomography) scan or bone scan.
- Hgb (hemoglobin) greater than or equal to 9 g/dL.
- Lymphocyte count greater than or equal to 500/mm(3).
- Hepatic function: Bilirubin less than or equal to 1.5 mg/dL, OR patients with Gilbert's
syndrome, a total bilirubin less than or equal to 3.0 mg/dL, AST (aspartate
aminotransferase) and ALT (alanine aminotransferase) less than 2.5 times upper limit of
normal
Design:
-Flutamide will be administered at a dose of 250 mg PO (by mouth) tid (three times a day)
every day in both arms A and B.
rV-PSATRICOM will be administered s.c. (subcutaneous) on day 1 in Arm B.
rF-PSATRICOM will be administered s.c. on day 29 & every 4 weeks in Arm B.
- For patients with declining PSA no restaging will be done unless they develop symptoms
consistent with metastatic disease.
- For patients with rising PSA, once 2 consecutive PSA rises are seen, a CT will be done
at their next scheduled visit. They will then be re-staged (CT and bone scans) at 3
month intervals as long as PSA continues to rise.
- After 3 months of therapy, patients receiving the flutamide alone (arm A) may cross over
to receive vaccine if they develop a rising PSA and scans are without metastatic
disease. The vaccine may commence 4 weeks after flutamide is stopped if the PSA
continues to rise. If there is an antiandrogen withdrawal response (a decline in PSA 28
days after the discontinuation of flutamide), PSA serum levels will be checked every 28
days and vaccine may commence when the serum PSA levels begin to rise (if scans are
negative for metastatsis). Patients on arm B will have flutamide discontinued and may
continue vaccine therapy. At this point patients may continue to receive treatment on
study until the development of disease on scans or a second occurrence of clinical
progression.
- Patients who have been on study for 2 years or more with stable disease and who are not
getting vaccine, clinic visits may be scheduled every 8 weeks. (Patients receiving
monthly vaccine will continue to have monthly visits.)
- For patients who have stable disease and attend clinic every 8 weeks, once 2 consecutive
PSA rises are seen, a CT and bone scan will be done at their next visit in 4 weeks. They
will then be restaged (CT and bone scans) at 3 month intervals as long as PSA continues
to rise.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |